Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Conditions: Pancreatic Adenocarcinoma; Ampulla of Vater Carcinoma; Adrenocortical Carcinoma; Neuroendocrine Carcinoma; Soft Tissue Sarcoma; Small Bowel Adenocarcinoma; Duodenum Adenocarcinoma; Gastric Adenocarcinoma Interventions: Drug: Dostarlimab; Drug: Chemotherapy Sponsors: UNICANCER; National Cancer Institute, France; GlaxoSmithKline Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Adrenocortical Carcinoma | Brain | Cancer | Cancer & Oncology | Carcinoma | Chemotherapy | Colorectal Cancer | Endometrial Cancer | France Health | Gastric (Stomach) Cancer | Gastroenterology | Neurology | Pancreas | Pancreatic Cancer | Research | Sarcomas | Soft Tissue Sarcoma